This article is more than 5 years old. Information may no longer be current.

Boehringer, Lilly resubmit empagliflozin application

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Boehringer Ingelheim and Eli Lilly and Company announced they have resubmitted the application for type 2 diabetes investigational drug empagliflozin.

After receiving a response letter in March from the FDA regarding “deficiencies” found at the Boehringer Ingelheim facility where empagliflozin was being manufactured, the two companies filed the class 1 resubmission. The FDA response at that time required no additional clinical testing for the drug, a sodium-glucose cotransporter 2, which had been involved in more than 10 multinational clinical trials with more than 13,000 participants with type 2 diabetes.

“We are very pleased to move forward with resubmission of the empagliflozin [new drug application] following a FDA inspection of the Boehringer Ingelheim facility referenced in the complete response letter,” Paul Fonteyne, president and CEO of Boehringer Ingelheim, said in a press release. “We believe in the potential of empagliflozin and hope to provide another treatment option in the near future to adults with type 2 diabetes.”